eye Insights Issue 02: Fueling a Revolution in Retinal Care

How biomedical breakthroughs in anti-VEGF research have changed how we diagnose, treat, and save vision for patients with retinal disease.

	Annually, 500,000 ophthalmic patients in the United States and over 1 million worldwide are treated with all anti-VEGF agents combined. Anti-VEGF treatments have been shown to halt vision loss in more than 90 percent of patients with AMD and to improve vision in one-third. VEGF inhibitors hold potential for a growing list of indications, including neovascular glaucoma and retinopathy of prematurity. VEGF inhibitors have been used experimentally to treat over 50 ocular diseases.

Annually, 500,000 ophthalmic patients in the United States and over 1 million worldwide are treated with all anti-VEGF agents combined.
Anti-VEGF treatments have been shown to halt vision loss in more than 90 percent of patients with AMD and to improve vision in one-third.
VEGF inhibitors hold potential for a growing list of indications, including neovascular glaucoma and retinopathy of prematurity.
VEGF inhibitors have been used experimentally to treat over 50 ocular diseases.

Inside:

Editor-in-Chief: Joan W. Miller, MD, FARVO
Managing Editor: Matthew F. Gardiner, MD
Communications Director: Suzanne Ward
Scientific Communications Manager: Wendy Chao, PhD
Clinical Advisory Group: Carolyn E. Kloek, MD, Deeba Husain, MD, Ankoor S. Shah, MD, PhD, Angela V. Turalba, MD

Browse all issues >> | Email: eyeinsights@meei.harvard.edu